The current immune standard of care for patients with MM includes monoclonal antibodies (such as nivolumab and pembrolizumab) targeting PD-1 and PD-L1 (34), as well as therapies targeting the CTLA-4 (such as ipilimumab) (35). This evidence concerns the gene CTLA4 and Miyoshi myopathy.